AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10364646 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric magnetic resonance imaging assessment
Number of subjects: 50
Study 7729304 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 2000
Study 7729304 — intervention group
Group type: COMPARATOR
Intervention: Non-digoxin
Number of subjects: 2000
Study 1781045 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conservation (tumor excised with tumor-free margins and subsequent radiotherapy)
Number of subjects: 905
Study 1781045 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy (modified radical procedure with axilla dissection)
Number of subjects: 905
Study 1781045 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conservation
Number of subjects: 905
Study 1781045 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 905
Study 1781045 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomized group (breast conservation)
Number of subjects: 905
Study 1781045 — intervention group
Group type: COMPARATOR
Intervention: Non-randomized group (mastectomy)
Number of subjects: 905
Study 7010161 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Number of subjects: 77
Study 7010161 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate
Number of subjects: 77
Study 7010161 — intervention group
Group type: COMPARATOR
Intervention: Oxymetholone
Number of subjects: 77
Study 7010161 — intervention group
Group type: COMPARATOR
Intervention: Fluoxymesterone
Number of subjects: 77
Study 30628526 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stabilization exercise therapy with bracing for 4 months
Number of subjects: 30
Study 30628526 — intervention group
Group type: COMPARATOR
Intervention: Scientific Exercises Approach to Scoliosis with bracing for 4 months
Number of subjects: 30
Study 28866370 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Inhibitory Pressure (DIP) on the biceps brachii myotendinous junction (10‐s pressure) with elbow at 120° (DIP120)
Number of subjects: 35
Study 28866370 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Inhibitory Pressure (DIP) on the biceps brachii myotendinous junction (10‐s pressure) with elbow at 180° (DIP180)
Number of subjects: 35
Study 28866370 — intervention group
Group type: COMPARATOR
Intervention: No Direct Inhibitory Pressure (Control)
Number of subjects: 35
Study 25739842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical thrust manipulation (n = 26)
Number of subjects: 78
Study 25739842 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder thrust manipulation (n = 27)
Number of subjects: 78
Study 25739842 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder exercise (n = 25)
Number of subjects: 78
Study 25739842 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (n = 25)
Number of subjects: 78
Study 23813218 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF; target plasma mycophenolic acid trough level of 1.5-2.5 µg/ml)
Number of subjects: 60
Study 23813218 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CsA; target trough level of 80-100 ng/ml)
Number of subjects: 60
Study 23813218 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 60
Study 23813218 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CsA)
Number of subjects: 60
Study 20970946 — intervention group
Group type: EXPERIMENTAL
Intervention: ASMA‐Undx (intervention group)
Number of subjects: 30
Study 20970946 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 30
Study 19203567 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. flumazenil 0.005 mg/kg
Number of subjects: 16
Study 19203567 — intervention group
Group type: COMPARATOR
Intervention: i.v. placebo
Number of subjects: 16
Study 19203567 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. flumazenil
Number of subjects: 16
Study 19203567 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam exposure
Number of subjects: 16
Study 18077945 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of oral pravastatin daily for 14 days
Number of subjects: 80
Study 18077945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15612962 — intervention group
Group type: EXPERIMENTAL
Intervention: Funhaler spacer device
Number of subjects: 32
Study 15612962 — intervention group
Group type: COMPARATOR
Intervention: Existing low volume spacer device
Number of subjects: 32
Study 12219805 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubbles method for visual information recognition
Number of subjects: 0
Study 9640557 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular AHA-blend cream
Number of subjects: 20
Study 9640557 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra strength AHA-blend cream
Number of subjects: 20
Study 9640557 — intervention group
Group type: COMPARATOR
Intervention: Control: non-AHA moisturizing lotion
Number of subjects: 20
Study 9922479 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA 300 mg per day (group II)
Number of subjects: 30
Study 9922479 — intervention group
Group type: COMPARATOR
Intervention: UDCA 150 mg per day (group I)
Number of subjects: 30
Study 9922479 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitary MCL
Number of subjects: 30
Study 9922479 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple MCL
Number of subjects: 30
Study 1833165 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20-40 mg/day) for 24 months
Number of subjects: 134
Study 1833165 — intervention group
Group type: COMPARATOR
Intervention: Captopril (75-150 mg/day) for 24 months
Number of subjects: 134
Study 6136841 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (200 mg every 6 h from 8 days before to 35 days after bone-marrow transplantation)
Number of subjects: 39
Study 6136841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 28370716 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Position Trainer
Number of subjects: 101
Study 28370716 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 101
Study 26748541 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephone counselling
Number of subjects: 1808
Study 26748541 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive telephone counselling
Number of subjects: 1808
Study 26748541 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet- and text-message-based intervention
Number of subjects: 1808
Study 26748541 — intervention group
Group type: COMPARATOR
Intervention: Self-help booklet (control)
Number of subjects: 1808
Study 24553304 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.08 mg/kg)
Number of subjects: 50
Study 24553304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24553304 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg)
Number of subjects: 50
Study 24553304 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 50
Study 22929301 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple touch immobilization (TTIm)
Number of subjects: 290
Study 22929301 — intervention group
Group type: COMPARATOR
Intervention: Single touch immobilization (STIm)
Number of subjects: 290
Study 20717839 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro models of AZD0865
Number of subjects: 0
Study 20717839 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical model for AZD0865
Number of subjects: 0
Study 20717839 — intervention group
Group type: COMPARATOR
Intervention: Clinical studies of AZD0865
Number of subjects: 0
Study 17638305 — intervention group
Group type: EXPERIMENTAL
Intervention: RTX 50 nM
Number of subjects: 58
Study 17638305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 15830402 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0
Study 15830402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11934348 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasburicase
Number of subjects: 0
Study 9059200 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms
Number of subjects: 30
Study 9059200 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 10 mg
Number of subjects: 30
Study 9059200 — intervention group
Group type: COMPARATOR
Intervention: Saline 1 ml
Number of subjects: 30
Study 8437966 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 13
Study 8437966 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Number of subjects: 13
Study 8437966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3527321 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ursodeoxycholic acid for 48 h before surgery
Number of subjects: 40
Study 3527321 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy
Number of subjects: 40
Study 29885745 — intervention group
Group type: EXPERIMENTAL
Intervention: autoVMAT plans
Number of subjects: 725
Study 29885745 — intervention group
Group type: COMPARATOR
Intervention: CLINICAL plans
Number of subjects: 725
Study 26596974 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg IV once daily
Number of subjects: 153
Study 26596974 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 200 mg IV once daily
Number of subjects: 153
Study 25001269 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetaphan (4 mg/min IV, autonomic blocked day)
Number of subjects: 21
Study 25001269 — intervention group
Group type: COMPARATOR
Intervention: Saline (intact day)
Number of subjects: 21
Study 22566392 — intervention group
Group type: EXPERIMENTAL
Intervention: External neck brace (ENB 1.0)
Number of subjects: 28
Study 22566392 — intervention group
Group type: COMPARATOR
Intervention: No external neck brace
Number of subjects: 28
Study 20131090 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of pain-related thoughts and feelings during cold pressor
Number of subjects: 222
Study 20131090 — intervention group
Group type: COMPARATOR
Intervention: No Suppression condition
Number of subjects: 222
Study 18377124 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive‐behavioral therapy (ICBT)
Number of subjects: 161
Study 18377124 — intervention group
Group type: EXPERIMENTAL
Intervention: Family cognitive‐behavioral therapy (FCBT)
Number of subjects: 161
Study 18377124 — intervention group
Group type: COMPARATOR
Intervention: Family-based education/support/attention (FESA)
Number of subjects: 161
Study 16210884 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg)
Number of subjects: 40
Study 16210884 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg)
Number of subjects: 40
Study 14641611 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT (grass or birch) + anti‐IgE
Number of subjects: 19
Study 14641611 — intervention group
Group type: COMPARATOR
Intervention: SIT (grass or birch) + placebo
Number of subjects: 19
Study 10594562 — intervention group
Group type: EXPERIMENTAL
Intervention: benznidazole therapy
Number of subjects: 41
Study 10594562 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study 8911861 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) 1 microgram i.v. alone and as pretreatment to oCRH (1 microgram kg‐1 BW i.v.)
Number of subjects: 8
Study 8911861 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin (DDAVP) as pretreatment to oCRH in normal subjects
Number of subjects: 8
Study 1736755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol ingestion (2 ml/kg of 50% vodka)
Number of subjects: 10
Study 1736755 — intervention group
Group type: COMPARATOR
Intervention: Control (room air or air/oxygen mixture)
Number of subjects: 10
Study 6371236 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 11
Study 6371236 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 11
Study 30686750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Number of subjects: 80
Study 30686750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 29397850 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTPO (15000 IU/d)
Number of subjects: 96
Study 29397850 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-11 (1.5 mg/d)
Number of subjects: 96
Study 29397850 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 96
Study 26803443 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV1/SERCA2a (1×10^13 DNase-resistant particles)
Number of subjects: 250
Study 26803443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 24114310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dismissing children
Number of subjects: 106
Study 24114310 — intervention group
Group type: COMPARATOR
Intervention: Secure children
Number of subjects: 106
Study 22399248 — intervention group
Group type: COMPARATOR
Intervention: PegIFN/RBV
Number of subjects: 24
Study 22399248 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride (15 mg/person/day) with PegIFN/RBV
Number of subjects: 24
Study 19887462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive protocol-based strategy involving bi-weekly visits for 16 weeks with medication adjustments as needed.
Number of subjects: 156
Study 19887462 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 156
Study 17699009 — intervention group
Group type: EXPERIMENTAL
Intervention: Western dietary pattern (highest quintile)
Number of subjects: 1009
Study 17699009 — intervention group
Group type: EXPERIMENTAL
Intervention: Prudent dietary pattern
Number of subjects: 1009
Study 16120136 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate cautery
Number of subjects: 97
Study 16120136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 11999090 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary heart disease prevalence diagnosed by history or ECG changes
Number of subjects: 1123
Study 11999090 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking/tobacco use
Number of subjects: 1123
Study 11999090 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 1123
Study 11999090 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (> or =140 and/or 90 mmHg)
Number of subjects: 1123
Study 11999090 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes (history or fasting glucose > or =126 mg/dl)
Number of subjects: 1123
Study 11999090 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI > or =27 kg/m2)
Number of subjects: 1123
Study 11999090 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncal obesity (waist:hip >0.9 males, >0.8 females)
Number of subjects: 1123
Study 11999090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia (low HDL-cholesterol <40 mg/dl)
Number of subjects: 1123
Study 11999090 — intervention group
Group type: EXPERIMENTAL
Intervention: High total cholesterol (> or =200 mg/dl)
Number of subjects: 1123
Study 11999090 — intervention group
Group type: EXPERIMENTAL
Intervention: High LDL-cholesterol (> or =130 mg/dl)
Number of subjects: 1123
Study 11999090 — intervention group
Group type: EXPERIMENTAL
Intervention: High triglycerides (> or =150 mg/dl)
Number of subjects: 1123
Study 9620811 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic nerve decompression surgery (ONDS)
Number of subjects: 0
Study 9620811 — intervention group
Group type: COMPARATOR
Intervention: Careful follow-up
Number of subjects: 0
Study 7611593 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cirrhosis
Number of subjects: 14
Study 7611593 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 14
Study 1692926 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 8
Study 1692926 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 8
Study 183084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine therapy with a low cholesterol diet
Number of subjects: 16
Study 183084 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-patient follow-up designed to reinforce patient motivation and dietary and drug adherence
Number of subjects: 16
Study 183084 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient studies
Number of subjects: 16
Study 31406538 — intervention group
Group type: COMPARATOR
Intervention: Intranasal steroids, antihistamines, leukotriene antagonists (Group 1)
Number of subjects: 60
Study 31406538 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture sessions (12 sessions, 2 sessions per week on specific acupuncture points) (Group 2)
Number of subjects: 60
Study 26188833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg combined with Simvastatin 10 mg (Vyto10)
Number of subjects: 204
Study 26188833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg combined with Simvastatin 20 mg (Vyto20)
Number of subjects: 204
Study 26188833 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg alone (Simva20)
Number of subjects: 204
Study 26188833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 23328284 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose treatment (n = 32)
Number of subjects: 97
Study 23328284 — intervention group
Group type: EXPERIMENTAL
Intervention: Live binary Bacillus subtilis treatment (n = 31)
Number of subjects: 97
Study 23328284 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (n = 34)
Number of subjects: 97
Study 19926201 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Hysterectomy (VH)
Number of subjects: 125
Study 19926201 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically Assisted Vaginal Hysterectomy (LAVH)
Number of subjects: 125
Study 19926201 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy (TLH)
Number of subjects: 125
Study 18190369 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding (regular diet within the first 8 hours)
Number of subjects: 200
Study 18190369 — intervention group
Group type: COMPARATOR
Intervention: Delayed feeding (oral fluids 4 hours after surgery, diet at 24 hours)
Number of subjects: 200
Study 18190369 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding
Number of subjects: 200
Study 18190369 — intervention group
Group type: COMPARATOR
Intervention: Delayed feeding
Number of subjects: 200
Study 15673875 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium 40 mg IM
Number of subjects: 0
Study 15673875 — intervention group
Group type: COMPARATOR
Intervention: Morphine 12 mg IM
Number of subjects: 0
Study 15673875 — intervention group
Group type: COMPARATOR
Intervention: Morphine 6 mg IM
Number of subjects: 0
Study 15673875 — intervention group
Group type: COMPARATOR
Intervention: Active treatment groups (Parecoxib sodium and morphine)
Number of subjects: 0
Study 12560309 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 MAC desflurane
Number of subjects: 16
Study 12560309 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 MAC desflurane
Number of subjects: 16
Study 10589357 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with cyclosporine (CSA) and methotrexate (MTX)
Number of subjects: 0
Study 10589357 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 0
Study 7847432 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 120
Study 7847432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 1940189 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox TC (1 tablet q.i.d., acid neutralizing capacity of 104 mEq/day)
Number of subjects: 50
Study 1940189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6210686 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g iv dose of mezlocillin
Number of subjects: 22
Study 6210686 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g iv dose of mezlocillin
Number of subjects: 22
Study 6210686 — intervention group
Group type: COMPARATOR
Intervention: 1 g dose during haemodialysis (HD)
Number of subjects: 22
Study 31103344 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating phylloquinone
Number of subjects: 103097
Study 31103344 — intervention group
Group type: EXPERIMENTAL
Intervention: Dephosphorylated uncarboxylated Matrix Gla Protein (dp-ucMGP)
Number of subjects: 103097
Study 29654841 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum Acupuncture (VA)
Number of subjects: 18
Study 29654841 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (AP)
Number of subjects: 18
Study 29654841 — intervention group
Group type: COMPARATOR
Intervention: Control Acupuncture (CA)
Number of subjects: 18
Study 27995880 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic dasatinib (100 mg dose)
Number of subjects: 12
Study 27995880 — intervention group
Group type: COMPARATOR
Intervention: Reference dasatinib (100 mg dose)
Number of subjects: 12
Study 25409454 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised feedback on alcohol intake and feedback on other health behaviours (n=659)
Number of subjects: 1330
Study 25409454 — intervention group
Group type: COMPARATOR
Intervention: Feedback on all health behaviours except alcohol intake (n=671)
Number of subjects: 1330
Study 23326976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Number of subjects: 112
Study 23326976 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 112
Study 20804269 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered psychotherapy for depression (16 weeks)
Number of subjects: 102
Study 18978165 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg zinc gluconate/d
Number of subjects: 387
Study 18978165 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg zinc gluconate/d
Number of subjects: 387
Study 18978165 — intervention group
Group type: COMPARATOR
Intervention: 0 mg zinc gluconate/d (placebo)
Number of subjects: 387
Study 16003508 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI findings in AC shoulders with IV Gd-chelate
Number of subjects: 26
Study 16003508 — intervention group
Group type: COMPARATOR
Intervention: MRI findings in healthy shoulders (control)
Number of subjects: 26